BRIP1: Options for Cancer Treatment

Cancer Treatment for People with Inherited BRIP1 Mutations

Inherited BRIP1 mutations may affect treatment options or eligibility for clinical trials studying which treatments work best. 

If you have an inherited BRIP1 mutation, have been diagnosed with cancer and any of the situations below apply to you, you may wish to speak to your doctor about your medical options. 

Regardless of cancer type, people with a BRIP1 mutation may benefit from biomarker testing and may qualify for clinical trials looking for more effective treatments for cancer.

PARP inhibitors for metastatic prostate cancer

The PARP inhibitor, Lynparza (olaparib) has received FDA-approval to treat men with metastatic, castration-resistant prostate cancer, who have a mutation in BRIP1 or another gene linked to a certain type of DNA damage repair. Lynparza may be used to treat men whose prostate cancer has progressed on enzalutamide (Xtandi) or abiraterone (Zytiga).

PARP inhibitors for advanced ovarian, fallopian tube or primary peritoneal cancer

Two PARP inhibitors have been approved as first-line maintenance therapy for ovarian cancer based on a tumor biomarker test known as an HRD test ("homologous recombination deficiency"). Cancers that test HRD-positive may be treated with Lynparza (olaparib) in combination with Avastin (bevacizumab) or Zejula (niraparib) alone as maintenance therapy after first-line platinum chemotherapy.

PARP inhibitors or other targeted therapies for advanced cancers with no other treatment options

If you have a BRIP1 mutation and advanced cancer that no longer responds to standard therapy, you may have additional options. Talk with your doctor about tumor testing to learn whether you might benefit from a PARP inhibitor, another targeted therapy or participation in a clinical trial. 

To learn more about treatment options for specific types of cancer, visit our section on Cancer Treatment by Cancer Type.